HSP70 Inhibition Blocks Adaptive Resistance and Synergizes with MEK Inhibition for the Treatment of NRAS-mutant Melanoma

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2022 Feb 21

PMID 35187538

Authors

Joshua L D Parris

Thibaut Barnoud

Julia I-Ju Leu

Jessica C Leung

Weili Ma

Nicole A Kirven

Adi Naryana Reddy Poli

Andrew V Kossenkov

Qin Liu

Joseph M Salvino

Donna L George

Ashani T Weeraratna

Qing Chen

Maureen E Murphy

Affiliations

Soon will be listed here.

Abstract

Significance: MEK inhibitors are currently used for NRAS-mutant melanoma, but have shown modest efficacy as single agents. This research shows a synergistic effect of combining HSP70 inhibitors with MEK inhibitors for the treatment of NRAS mutant melanoma.

Citing Articles

An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression.

Indeglia A, Leung J, Miller S, Leu J, Dougherty J, Clarke N Cancer Discov. 2023; 13(7):1696-1719.

PMID: 37140445 PMC: 10326602. DOI: 10.1158/2159-8290.CD-22-1315.

Targeting ErbB3 and Cellular NADPH/NADP Abundance Sensitizes Cutaneous Melanomas to Ferroptosis Inducers.

Leu J, Murphy M, George D ACS Chem Biol. 2022; 17(5):1038-1044.

PMID: 35420772 PMC: 9208338. DOI: 10.1021/acschembio.2c00113.

References

Mern D, Hasskarl J, Burwinkel B . Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells. Br J Cancer. 2010; 103(8):1237-44. PMC: 2967066. DOI: 10.1038/sj.bjc.6605897. View

Zhang L, Zhang S, Yao J, Lowery F, Zhang Q, Huang W . Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015; 527(7576):100-104. PMC: 4819404. DOI: 10.1038/nature15376. View

Liu Q, Yin X, Languino L, Altieri D . Evaluation of drug combination effect using a Bliss independence dose-response surface model. Stat Biopharm Res. 2019; 10(2):112-122. PMC: 6415926. DOI: 10.1080/19466315.2018.1437071. View

Almeida F, Douglass S, Fane M, Weeraratna A . Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma. Pigment Cell Melanoma Res. 2018; 32(2):237-247. PMC: 6727967. DOI: 10.1111/pcmr.12736. View

Li B, Dewey C . RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12:323. PMC: 3163565. DOI: 10.1186/1471-2105-12-323. View

Babiker H, Byron S, Hendricks W, Elmquist W, Gampa G, Vondrak J . E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. Invest New Drugs. 2018; 37(4):636-645. PMC: 7519637. DOI: 10.1007/s10637-018-0668-8. View

Phadke M, Ozgun A, Eroglu Z, Smalley K . Melanoma brain metastases: Biological basis and novel therapeutic strategies. Exp Dermatol. 2021; 31(1):31-42. DOI: 10.1111/exd.14286. View

Luis Manzano J, Layos L, Buges C, de Los Llanos Gil M, Vila L, Martinez-Balibrea E . Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med. 2016; 4(12):237. PMC: 4930524. DOI: 10.21037/atm.2016.06.07. View

Lin Q, Balasubramanian K, Fan D, Kim S, Guo L, Wang H . Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia. 2010; 12(9):748-54. PMC: 2933695. DOI: 10.1593/neo.10602. View

10.

Kim S, Kim J, Park E, Lee J, Lin Q, Langley R . Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia. 2011; 13(3):286-98. PMC: 3050871. DOI: 10.1593/neo.11112. View

11.

Zou Y, Watters A, Cheng N, Perry C, Xu K, Alicea G . Polyunsaturated Fatty Acids from Astrocytes Activate PPARγ Signaling in Cancer Cells to Promote Brain Metastasis. Cancer Discov. 2019; 9(12):1720-1735. PMC: 6891206. DOI: 10.1158/2159-8290.CD-19-0270. View

12.

Roschger C, Cabrele C . The Id-protein family in developmental and cancer-associated pathways. Cell Commun Signal. 2017; 15(1):7. PMC: 5267474. DOI: 10.1186/s12964-016-0161-y. View

13.

Gampa G, Kim M, Cook-Rostie N, Laramy J, Sarkaria J, Paradiso L . Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases. Drug Metab Dispos. 2018; 46(5):658-666. PMC: 5896365. DOI: 10.1124/dmd.117.079194. View

14.

Echevarria-Vargas I, Villanueva J . COMBATING NRAS MUTANT MELANOMA: FROM BENCH TO BEDSIDE. Melanoma Manag. 2018; 4(4):183-186. PMC: 5959291. DOI: 10.2217/mmt-2017-0023. View

15.

Jakob J, Bassett Jr R, Ng C, Curry J, Joseph R, Alvarado G . NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2011; 118(16):4014-23. PMC: 3310961. DOI: 10.1002/cncr.26724. View

16.

McCubrey J, Steelman L, Chappell W, Abrams S, Wong E, Chang F . Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2006; 1773(8):1263-84. PMC: 2696318. DOI: 10.1016/j.bbamcr.2006.10.001. View

17.

Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth R, Yang H . A New Bliss Independence Model to Analyze Drug Combination Data. J Biomol Screen. 2014; 19(5):817-21. DOI: 10.1177/1087057114521867. View

18.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

19.

Wasilewski D, Priego N, Fustero-Torre C, Valiente M . Reactive Astrocytes in Brain Metastasis. Front Oncol. 2018; 7:298. PMC: 5732246. DOI: 10.3389/fonc.2017.00298. View

20.

Nazarian R, Shi H, Wang Q, Kong X, Koya R, Lee H . Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326):973-7. PMC: 3143360. DOI: 10.1038/nature09626. View